Barclays
HOWL icon

Barclays’s Werewolf Therapeutics HOWL Stock Holding History

Barclays’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76K Hold
13,235
– – ﹤0.01% 4782
2026
Q1 		$11K Sell
13,235
-1
-0% -$1 ﹤0.01% 4685
2025
Q4 		$8.39K Sell
13,236
-39
-0.3% -$47 ﹤0.01% 4951
2025
Q3 		$26.2K Buy
13,275
+39
+0.3% +$53 ﹤0.01% 4901
2025
Q2 		$14.4K Sell
13,236
-32,125
-71% -$33.1K ﹤0.01% 4882
2025
Q1 		$44.1K Sell
45,361
-14,387
-24% -$18.8K ﹤0.01% 4647
2024
Q4 		$88.4K Buy
59,748
+4,938
+9% +$10.1K ﹤0.01% 4624
2024
Q3 		$116K Buy
54,810
+30,990
+130% +$70.5K ﹤0.01% 4533
2024
Q2 		$58.1K Buy
23,820
+21,942
+1,168% +$105K ﹤0.01% 4144
2024
Q1 		$12.2K Buy
+1,878
New +$10.9K ﹤0.01% 4794
2022
Q3 		– Sell
-108
Closed – – 4940
2022
Q2 		$0 Sell
108
-4,179
-97% -$19.1K ﹤0.01% 5132
2022
Q1 		$19K Buy
+4,287
New +$30K ﹤0.01% 4461

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays's HOWL Position: Q2 2026 in Review

Barclays held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 13,235 shares worth $4.76K. The position accounts for ﹤0.01% of the portfolio, ranked #4782.

Barclays first reported a position in HOWL in Q1 2022 and has held it in 12 quarters since. The position peaked at $116K in Q3 2024. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Barclays held 13,235 shares of Werewolf Therapeutics worth $4.76K as of Q2 2026.
  • Barclays left its Werewolf Therapeutics share count unchanged in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4782 holding.
  • Barclays first reported a position in Werewolf Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • Barclays's Werewolf Therapeutics position peaked at $116K in Q3 2024.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.